Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
- DOI
- 10.1016/s1474-4422(26)00278-4
- Published
- 2026 Oct
- Container
- The Lancet. Neurology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1474-4422-26-00278-4,
title = {Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.},
author = {Plazzi G and Grunstein RR and Mignot E and Lammers GJ and Plante DT and Buntinx E and Del Río Villegas R and Chen H and Lovett A and Doane MJ and Hopkinson C and Rege B and Himes J and Dauvilliers Y},
year = {2026},
journal = {The Lancet. Neurology},
doi = {10.1016/s1474-4422(26)00278-4},
url = {https://doi.org/10.1016/s1474-4422(26)00278-4}
}RIS
TY - JOUR TI - Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial. AU - Plazzi G AU - Grunstein RR AU - Mignot E AU - Lammers GJ AU - Plante DT AU - Buntinx E AU - Del Río Villegas R AU - Chen H AU - Lovett A AU - Doane MJ AU - Hopkinson C AU - Rege B AU - Himes J AU - Dauvilliers Y PY - 2026 JO - The Lancet. Neurology DO - 10.1016/s1474-4422(26)00278-4 UR - https://doi.org/10.1016/s1474-4422(26)00278-4 ER -
APA
G, P., RR, G., E, M., GJ, L., DT, P., E, B., R, D. R. V., H, C., A, L., MJ, D., C, H., B, R., J, H., & Y, D. (2026). Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(26)00278-4
Source records
- pubmed · retrieved 2026-09-27T07:08:45.713Z